A2M China label infant formula Source: Synlait Milk
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Synlait Milk (SM1) secures approval from China’s State Administration for Market Regulation to re-register the a2 Milk Company’s (A2M) Chinese-label infant milk formula (IMF)
  • The IMF product is approved for three stages and is formulated in line with China’s national GB standards
  • SM1 claims the re-registration is “pivotal” for its ongoing manufacturing and supply agreement with the a2 Milk Company, which will export its IMF product into Chinese markets until September 2027
  • Production at the Dunsandel facility is expected to begin this month, ahead of commercialisation 1H 2024
  • SM1 shares were trading at $1.65, while A2M was at $5.71 at 10:45 am AEST

Synlait Milk (SM1) has received approval from China’s State Administration for Market Regulation (SAMR) to re-register the a2 Milk company’s (A2M) Chinese-label infant milk formula (IMF).

The IMF product has been approved for three stages, and has been formulated in line with China’s national GB standards at Synlait’s Dunsandel facility.

The approval will allow the company to manufacture and export the IMF for Chinese markets until September 2027.

SM1 claims the re-registration is “pivotal” for its ongoing manufacturing and supply agreement with the a2 Milk company.

“We are thrilled to have achieved this significant milestone, which is pivotal to the long-term success of our Advanced Nutrition business,” Synlait CEO Grant Watson said.

“Synlait and The a2 Milk Company have a long-standing and complementary partnership, and we look forward to continuing to support their China growth ambitions.”

Production at the Dunsandel facility is expected to begin this month ahead of commercialisation in the first half of 2024.

The a2 Milk Company Managing Director and CEO David Bortolussi said the approval provided the company with continued access to China’s substantial milk formula market, which remains a “key” focus of the company’s refreshed growth strategy.

SM1 shares were up 10.7 per cent, trading at $1.65, while A2M shares were up 6.93 per cent to $5.71 at 10:45 am AEST.

SM1 by the numbers
More From The Market Online
Children's hospital concept

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host…
Iran oil concept

Forget tariffs. If Trump really does bomb Iran, oil-price-linked inflation is back on cards

Right now, the world is bracing for the Trump 2.0 Administration's 'reciprocal tariffs' which are set…
Seaweed

Can you really get gold and silver out of seaweed? It turns out, yes you can

BPH Global is an interesting offering on the ASX: It's extracting precious metals from seaweeds cultivated…

Hollista Coltech sues ProImmune Director in WA court after US case dismissal

Malaysia-focused "premium grade collagen" and natural foods player Hollista Coltech (ASX:HCT) has had its shares suspended…